

Dan Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11286431/publications.pdf>

Version: 2024-02-01

136
papers

11,932
citations

22153

59
h-index

26613

107
g-index

137
all docs

137
docs citations

137
times ranked

9581
citing authors

#	ARTICLE	IF	CITATIONS
1	Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9448-9453.	7.1	1,537
2	The Chemokine Receptor CXCR4 Is Required for the Retention of B Lineage and Granulocytic Precursors within the Bone Marrow Microenvironment. Immunity, 1999, 10, 463-471.	14.3	635
3	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, 107, 3469-3473.	1.4	371
4	MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 2007, 109, 500-502.	1.4	363
5	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510.	1.6	355
6	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome- <i>positive</i> (Ph+) acute lymphoblastic leukemia. Blood, 2010, 116, 2070-2077.	1.4	319
7	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 2007, 110, 4005-4011.	1.4	284
8	Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clinical Cancer Research, 2005, 11, 3425-3432.	7.0	256
9	Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase. Journal of Clinical Oncology, 2010, 28, 392-397.	1.6	231
10	Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 398-404.	1.6	227
11	Precursor B-cell Lymphoblastic Lymphoma. American Journal of Surgical Pathology, 2000, 24, 1480-1490.	3.7	203
12	TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood, 2003, 101, 5007-5009.	1.4	182
13	A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood, 2004, 104, 328-335.	1.4	182
14	Absence of CD26 Expression Is a Useful Marker for Diagnosis of T-Cell Lymphoma in Peripheral Blood. American Journal of Clinical Pathology, 2001, 115, 885-892.	0.7	179
15	The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood, 2000, 95, 627-632.	1.4	178
16	Primary-Effusion Lymphoma and Kaposi's Sarcoma in a Cardiac-Transplant Recipient. New England Journal of Medicine, 1998, 339, 444-449.	27.0	169
17	Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome- <i>positive</i> chronic-phase chronic myeloid leukemia after failure of interferon- γ . Blood, 2004, 104, 1979-1988.	1.4	163
18	Philadelphia Chromosome- <i>Positive</i> Acute Myeloid Leukemia. American Journal of Clinical Pathology, 2007, 127, 642-650.	0.7	163

#	ARTICLE	IF	CITATIONS
19	CD4+/CD56+ Hematodermic Tumor. American Journal of Clinical Pathology, 2007, 127, 687-700.	0.7	158
20	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood, 2009, 113, 6315-6321.	1.4	153
21	Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 2009, 113, 2154-2160.	1.4	151
22	Dasatinib (BMS-354825) is active in Philadelphia chromosome ⁺ positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood, 2007, 109, 497-499.	1.4	150
23	Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood, 2008, 111, 1774-1780.	1.4	140
24	Expression pattern of T-cell ⁺ associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood, 2000, 96, 685-690.	1.4	138
25	Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. British Journal of Haematology, 2007, 136, 439-447.	2.5	137
26	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood, 2002, 100, 3369-3373.	1.4	133
27	CD56 ⁺ TdT ⁺ blastic natural killer cell tumor of the skin. Cancer, 2002, 94, 2401-2408.	4.1	128
28	Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood, 2008, 112, 53-55.	1.4	127
29	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
30	Expression of Stromal-Derived Factor-1 Is Decreased by IL-1 and TNF and in Dermal Wound Healing. Journal of Immunology, 2001, 166, 5749-5754.	0.8	126
31	Eradication of minimal residual disease in hairy cell leukemia. Blood, 2006, 107, 4658-4662.	1.4	120
32	Kinase domain point mutations in Philadelphia chromosome ⁺ positive acute lymphoblastic leukemia emerge after therapy with BCR ⁺ ABL kinase inhibitors. Cancer, 2008, 113, 985-994.	4.1	120
33	High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood, 2008, 111, 328-337.	1.4	120
34	Hepatosplenic gamma/delta T-Cell Lymphoma in Bone Marrow. American Journal of Clinical Pathology, 2001, 116, 410-419.	0.7	107
35	Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman ⁺ disease. Human Pathology, 2003, 34, 835-840.	2.0	102
36	Phase II Study of Denileukin Diftitox for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2004, 22, 4095-4102.	1.6	98

#	ARTICLE	IF	CITATIONS
37	Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. <i>Modern Pathology</i> , 2004, 17, 954-961.	5.5	98
38	Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance. <i>Journal of Clinical Oncology</i> , 2009, 27, 3642-3649.	1.6	94
39	Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2002, 26, 630-636.	3.7	91
40	Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2145-2155.	4.1	91
41	High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 4675-4686.	1.4	88
42	Mantle Cell Lymphoma Involving Skin. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1312-1318.	3.7	86
43	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. <i>Blood</i> , 2006, 108, 1421-1423.	1.4	85
44	Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. <i>Modern Pathology</i> , 2006, 19, 1555-1562.	5.5	84
45	A Novel Four-Color PCR Assay to Assess T-Cell Receptor Gamma Gene Rearrangements in Lymphoproliferative Lesions. <i>American Journal of Clinical Pathology</i> , 2001, 116, 17-24.	0.7	83
46	A Chromosomal Abnormality in Hyaline Vascular Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2000, 24, 882-888.	3.7	82
47	The T-Cell Chemokine Receptor CXCR3 Is Expressed Highly in Low-Grade Mycosis Fungoides. <i>American Journal of Clinical Pathology</i> , 2001, 115, 413-421.	0.7	80
48	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	1.4	77
49	Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. <i>Blood</i> , 2008, 112, 4839-4842.	1.4	75
50	Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 465-472.	1.3	73
51	Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 4-11.	2.8	72
52	Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Cancer</i> , 2011, 117, 1800-1811.	4.1	72
53	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. <i>Blood</i> , 2011, 117, 3641-3647.	1.4	71
54	JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. <i>Modern Pathology</i> , 2005, 18, 1365-1370.	5.5	69

#	ARTICLE	IF	CITATIONS
55	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002, 94, 1731-1738.	4.1	67
56	Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. <i>Journal of Clinical Oncology</i> , 2009, 27, 5425-5430.	1.6	67
57	Primary cutaneous B-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 478-483.	1.2	65
58	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin's Disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 377-383.	2.0	64
59	CD4 ⁺ CD8 ⁻ 'Double-Negative' Cutaneous T-Cell Lymphomas Share Common Histologic Features and an Aggressive Clinical Course. <i>American Journal of Surgical Pathology</i> , 2002, 26, 225-231.	3.7	63
60	Primary S ₁₀₀ β ⁺ Syndrome Commonly Shows Low-Grade Cytologic Atypia and an Absence of Epidermotropism. <i>American Journal of Clinical Pathology</i> , 2005, 123, 510-515.	0.7	59
61	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.7	58
62	A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. <i>BMC Clinical Pathology</i> , 2002, 2, 5.	1.8	58
63	Flow cytometric detection of peripheral blood involvement by mycosis fungoides and S ₁₀₀ β ⁺ syndrome using T-cell receptor Vβ2 chain antibodies and its application in blood staging. <i>Modern Pathology</i> , 2010, 23, 284-295.	5.5	58
64	Dissolution of the Lymphoid Follicle Is a Feature of the HHV8+ Variant of Plasma Cell Castleman's Disease. <i>American Journal of Surgical Pathology</i> , 2003, 27, 91-100.	3.7	54
65	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 489-495.	3.7	52
66	Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses. <i>Clinical Cancer Research</i> , 2007, 13, 6666-6672.	7.0	52
67	Reticulum Cell Sarcoma of Lymph Node with Mixed Dendritic and Fibroblastic Features. <i>Modern Pathology</i> , 2001, 14, 1059-1067.	5.5	51
68	Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. <i>Human Pathology</i> , 2005, 36, 747-755.	2.0	51
69	T-Cell Prolymphocytic Leukemia Involving Extramedullary Sites. <i>American Journal of Clinical Pathology</i> , 2005, 123, 456-464.	0.7	50
70	CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 480-484.	1.2	47
71	Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. <i>Cancer</i> , 2011, 117, 572-580.	4.1	46
72	Distribution and Prognosis of WHO Lymphoma Subtypes in Taiwan Reveals a Low Incidence of Germinal-Center Derived Tumors. <i>Leukemia and Lymphoma</i> , 2004, 45, 1375-1384.	1.3	45

#	ARTICLE	IF	CITATIONS
73	c-Jun Expression and Activation are Restricted to CD30+ Lymphoproliferative Disorders. American Journal of Surgical Pathology, 2007, 31, 447-453.	3.7	42
74	Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. Modern Pathology, 2005, 18, 1343-1349.	5.5	40
75	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood, 2008, 112, 5190-5192.	1.4	36
76	Dismantling the Germinal Center: Comparing the Processes of Transformation, Regression, and Fragmentation of the Lymphoid Follicle. Advances in Anatomic Pathology, 2002, 9, 129-138.	4.3	34
77	Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue Site. Clinical Cancer Research, 2004, 10, 5587-5594.	7.0	34
78	EBV-Associated B-and T-Cell Posttransplant Lymphoproliferative Disorders Following Primary EBV Infection in a Kidney Transplant Recipient. American Journal of Clinical Pathology, 2005, 123, 222-228.	0.7	34
79	Cutaneous T-Cell and NK-Cell Lymphomas. American Journal of Clinical Pathology, 2007, 127, 670-686.	0.7	34
80	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34
81	Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. British Journal of Haematology, 2005, 130, 726-728.	2.5	33
82	T Cell Leukemia-1 Modulates TCR Signal Strength and IFN- γ Levels through Phosphatidylinositol 3-Kinase and Protein Kinase C Pathway Activation. Journal of Immunology, 2005, 175, 864-873.	0.8	33
83	Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. Histopathology, 2010, 57, 785-795.	2.9	32
84	T-Cell Prolymphocytic Leukemia: A Single-Institution Experience. Clinical Lymphoma and Myeloma, 2005, 6, 234-239.	1.4	31
85	Apoptosis and Proliferation in Subcutaneous Panniculitis-Like T-Cell Lymphoma. Modern Pathology, 2002, 15, 625-631.	5.5	30
86	Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer, 2010, 116, 3631-3637.	4.1	29
87	Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia. Leukemia and Lymphoma, 2018, 59, 1008-1011.	1.3	29
88	Mature T-cell leukemias. Cancer, 2005, 104, 1808-1818.	4.1	28
89	TCL1 in B-cell Tumors Retains its Normal B-cell Pattern of Regulation and is a Marker of Differentiation Stage. American Journal of Surgical Pathology, 2007, 31, 1123-1129.	3.7	28
90	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. International Journal of Dermatology, 2001, 40, 505-511.	1.0	27

#	ARTICLE	IF	CITATIONS
91	Cutaneous and Systemic Plasmacytosis in a Patient of Asian Descent Living in the United States. <i>American Journal of Dermatopathology</i> , 2002, 24, 241-245.	0.6	27
92	Cytogenetic anomalies in hyaline vascular Castleman disease: report of two cases with reappraisal of histogenesis. <i>Cancer Genetics and Cytogenetics</i> , 2006, 164, 110-117.	1.0	27
93	T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 163-172.	2.3	27
94	Differential Expression of WT1 Gene Product in Non-Hodgkin Lymphomas. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2005, 13, 132-137.	2.0	26
95	Peripheral T-Cell Lymphoma Arising in the Liver. <i>American Journal of Clinical Pathology</i> , 2002, 118, 574-581.	0.7	25
96	The oncogenic <sc>JUNB</sc>/<sc>CD</sc>30 axis contributes to cell cycle deregulation in <sc>ALK</sc>+ anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2014, 167, 514-523.	2.5	25
97	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	1.4	24
98	Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 182-182.	1.4	24
99	Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 546-555.	2.8	23
100	TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10175-10180.	7.1	22
101	Phenotypic Characterization of Subsets of T Cell Lymphoma: Towards a Functional Classification of T Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 40, 449-459.	1.3	20
102	The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas. <i>Cancer</i> , 2008, 112, 552-561.	4.1	19
103	Cytologic Diagnosis of Primary Serous Lymphoma. <i>American Journal of Clinical Pathology</i> , 1996, 106, 359-364.	0.7	18
104	Utility of CD26 in flow cytometric immunophenotyping of T-cell lymphomas in tissue and body fluid specimens. <i>Cytometry Part B - Clinical Cytometry</i> , 2008, 74B, 341-348.	1.5	18
105	Resistance mechanism for ibrutinib in marginal zone lymphoma. <i>Blood Advances</i> , 2019, 3, 500-502.	5.2	17
106	Peripheral T-Cell Lymphoma With a “Follicular” Pattern and the Perifollicular Sinus Phenotype. <i>American Journal of Clinical Pathology</i> , 2005, 123, 448-455.	0.7	16
107	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.6	14
108	Skin involvement in T-cell prolymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 533-534.	1.2	14

#	ARTICLE	IF	CITATIONS
109	The Current State and Future of Clonality Studies in Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2003, 121, ix-x.	0.7	13
110	Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. <i>Cancer Science</i> , 2010, 101, 2005-2010.	3.9	13
111	Recurrences in Nodal T-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2000, 114, 438-447.	0.7	12
112	The Role of the Perifollicular Sinus in Determining the Complex Immunoarchitecture of Angioimmunoblastic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1632-1640.	3.7	12
113	A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Modern Pathology</i> , 2010, 23, 1524-1534.	5.5	12
114	Virtual Airway Skills Trainer (VAST) Simulator. <i>Studies in Health Technology and Informatics</i> , 2016, 220, 91-7.	0.3	12
115	Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. <i>Oncology Reports</i> , 2003, 10, 1513-8.	2.6	12
116	Histiocytic and Dendritic Cell Neoplasms. <i>Surgical Pathology Clinics</i> , 2010, 3, 1165-1183.	1.7	11
117	Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. <i>Blood</i> , 2010, 115, 5428-5429.	1.4	10
118	Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). <i>Blood</i> , 2008, 112, 446-446.	1.4	9
119	Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2006, 6, 831-841.	3.1	5
120	CD56 TdT blastic natural killer cell tumor of the skin. <i>Cancer</i> , 2002, 94, 2401-2408.	4.1	5
121	Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1478-1484.	1.3	4
122	Cutaneous T-cell Lymphomas. , 2010, , 427-447.		3
123	Functional Classification of Peripheral T-Cell Lymphomas as an Approach to Improve Outcome Prediction and Therapy Selection. <i>Seminars in Hematology</i> , 2010, 47, S1-S4.	3.4	3
124	Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines. <i>Leukemia Research</i> , 2017, 60, 129-134.	0.8	3
125	Molecular and Cytogenetic Education in Hematopathology Fellowship. <i>American Journal of Clinical Pathology</i> , 2019, 152, 438-445.	0.7	3
126	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3049-3049.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Reply to the Letter to the Editor from Oudejans et al. <i>Clinical Cancer Research</i> , 2008, 14, 2515-2515.	7.0	1
128	Approaches to Classification of Lymphoma and Leukemia. , 2010, , 3-20.		1
129	Rooting into the Soil, a Model for the Role of Sox4 in Leukemia. <i>Blood</i> , 2008, 112, 3794-3794.	1.4	1
130	Molecular Diagnostics and Cytogenetic Testing. , 2010, , 61-95.		0
131	Classification of T-cell and NK-cell Malignancies. , 2010, , 391-412.		0
132	Histiocytic and Dendritic Cell Neoplasms. , 2010, , 459-475.		0
133	Designing Targeted Therapies for Lymphomas and Leukemias. , 2010, , 611-626.		0
134	Dynamics of BCR-ABL1 Transcripts during Dasatinib Therapy in Patients with Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2007, 110, 2962-2962.	1.4	0
135	Dynamics of BCR-ABL1 Transcripts during Nilotinib Therapy in Patients with Chronic Myeloid Leukemia (CML).. <i>Blood</i> , 2007, 110, 2961-2961.	1.4	0
136	Chronic Myelogenous Leukemia. <i>Molecular Pathology Library</i> , 2010, , 387-394.	0.1	0